TY - JOUR
T1 - Quality of life in congenital, untreated, lifetime isolated growth hormone deficiency
AU - Barbosa, Jorge A.R.
AU - Salvatori, Roberto
AU - Oliveira, Carla R.P.
AU - Pereira, Rossana M.C.
AU - Farias, Catarine T.
AU - Britto, Allan V.de O.
AU - Farias, Natália T.
AU - Blackford, Amanda
AU - Aguiar-Oliveira, Manuel H.
N1 - Funding Information:
This work was funded in part by National Institutes of Health (NIH) Grant 1 R01 DK065718 and by a grant from the Genentech Center for Clinical Research in Endocrinology (both to R.S.). The NIH and Genenetech had no further role in study design; in the collection, analysis, and interpretation of data; in writing of the report; and in the decision to submit the paper for publication.
PY - 2009/7
Y1 - 2009/7
N2 - Impaired quality of life (QoL) is commonly described as being associated with growth hormone (GH) deficiency (GHD), and beneficial effects of GH replacement therapy on QoL have been reported. However, most studies examined heterogeneous cohorts of patients GHD of varying etiologies, severities and age of onset. Most of these patients miss other pituitary hormones, whose replacement can also influence QoL. We studied the QoL of a homogeneous cohort of 20 adults with isolated GH deficiency (IGHD) due to the same mutation in the GH-releasing hormone receptor gene (IGHD, 10 men) using the Life Satisfaction Hypopituitarism Module (QLS-H), and compared them with 20 matched controls residing in the same community (CO, 10 men). Additionally, the IGHD group was evaluated after 6 months of treatment with bi-monthly depot GH, and after 12 months from its interruption. There was no difference in the total score of QoL (TSQoL) or in any of the nine categories that composes the questionnaire between IGHD and CO. Similar results were obtained when data were analyzed by sex. GH treatment only increased satisfaction with physical endurance, but did not cause an increase in the TSQoL. We conclude that in this unique population congenital, untreated, lifetime IGHD does not reduce QoL, and treatment with GH for 6 months only causes improvement in satisfaction with physical resistance.
AB - Impaired quality of life (QoL) is commonly described as being associated with growth hormone (GH) deficiency (GHD), and beneficial effects of GH replacement therapy on QoL have been reported. However, most studies examined heterogeneous cohorts of patients GHD of varying etiologies, severities and age of onset. Most of these patients miss other pituitary hormones, whose replacement can also influence QoL. We studied the QoL of a homogeneous cohort of 20 adults with isolated GH deficiency (IGHD) due to the same mutation in the GH-releasing hormone receptor gene (IGHD, 10 men) using the Life Satisfaction Hypopituitarism Module (QLS-H), and compared them with 20 matched controls residing in the same community (CO, 10 men). Additionally, the IGHD group was evaluated after 6 months of treatment with bi-monthly depot GH, and after 12 months from its interruption. There was no difference in the total score of QoL (TSQoL) or in any of the nine categories that composes the questionnaire between IGHD and CO. Similar results were obtained when data were analyzed by sex. GH treatment only increased satisfaction with physical endurance, but did not cause an increase in the TSQoL. We conclude that in this unique population congenital, untreated, lifetime IGHD does not reduce QoL, and treatment with GH for 6 months only causes improvement in satisfaction with physical resistance.
KW - Brazil
KW - GH treatment
KW - GHRH receptor mutation
KW - Isolated growth hormone deficiency
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=67349159878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349159878&partnerID=8YFLogxK
U2 - 10.1016/j.psyneuen.2009.01.001
DO - 10.1016/j.psyneuen.2009.01.001
M3 - Article
C2 - 19181452
AN - SCOPUS:67349159878
SN - 0306-4530
VL - 34
SP - 894
EP - 900
JO - Psychoneuroendocrinology
JF - Psychoneuroendocrinology
IS - 6
ER -